Click image to enlarge
The
V-PLEX platform offers analytically validated singleplex and multiplex assay kits. Developed under rigorous design control, V-PLEX kits provide accurate and reproducible results with consistency from lot to lot. The V-PLEX Chemokine Panel 1 (human) Gen. B Kit includes nine biomarkers that are associated with the inflammatory response and immune system regulation (Table 1). The assays can be used for quantitative measurements in the sample types listed in the “Specifications” tab below and offer sensitivity limits (LLODs and LLOQs) in the sub- to low pg/mL range.
| Analyte |
LLOD |
LLOQ |
ULOQ |
Dynamic Range |
Unit |
| Eotaxin |
0.20 |
2.14 |
910 |
0.20 - 910 |
pg/mL |
| Eotaxin-3 |
1.44 |
11.1 |
11,100 |
1.44 - 11,100 |
pg/mL |
| IP-10 |
0.12 |
1.29 |
1,240 |
0.12 - 1,240 |
pg/mL |
| MCP-1 |
0.16 |
1.45 |
247 |
0.16 - 247 |
pg/mL |
| MCP-4 |
0.05 |
0.518 |
234 |
0.05 - 0.518 |
pg/mL |
| MDC |
1.00 |
6.43 |
2,930 |
1.00 - 2,930 |
pg/mL |
| MIP-1α |
0.05 |
0.357 |
403 |
0.05 - 403 |
pg/mL |
| MIP-1β |
0.09 |
1.20 |
390 |
0.09 - 390 |
pg/mL |
| TARC |
0.11 |
2.14 |
481 |
0.11 - 481 |
pg/mL |
-
-
Specifications
-
Kit Contents
-
Documentation
-
References
|
Analyte(s)
|
|
Eotaxin, Eotaxin-3, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, TARC
|
|
|
Species
|
|
Human
|
|
|
Instrument(s)
|
|
SECTOR Imager 2400
,
MESO QuickPlex SQ 120MM
,
MESO SECTOR S 600
,
SECTOR Imager 6000
,
MESO SECTOR S 600MM
,
MESO QuickPlex SQ 120
|
|
|
Plate Type
|
|
96-well
|
|
|
Sample Type
|
|
Serum, Plasma, Urine, CSF, Cell Culture Supernatant
|
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
|
Storage Condition
|
|
Multi-Component
|
|
|
Schedule B Code
|
|
3822.19.0000
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
|
2-8 °C
|
1 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(75 μL)
|
|
|
|
Chemokine Panel 1 (human) Gen. B SECTOR Plate
|
2-8 °C
|
1 each
(1 each)
|
|
|
|
Diluent Assembly 33 (includes Diluent 3 - 8mL and Diluent 57 - 10 mL)
|
≤-10 °C
|
1 each
(1 each)
|
|
|
|
|
RT
|
1 bottle
(18 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
|
2-8 °C
|
5 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
Chemokine Panel 1 (human) Gen. B SECTOR Plate
|
2-8 °C
|
5 each
(1 each)
|
|
|
|
Diluent Assembly 34 (includes Diluent 3 - 40mL and Diluent 57 - 50 mL)
|
≤-10 °C
|
1 each
(1 each)
|
|
|
|
|
RT
|
1 bottle
(90 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
|
2-8 °C
|
25 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
|
2-8 °C
|
5 vial
(375 μL)
|
|
|
|
Chemokine Panel 1 (human) Gen. B SECTOR Plate
|
2-8 °C
|
25 each
(1 each)
|
|
|
|
Diluent Assembly 34 (includes Diluent 3 - 40mL and Diluent 57 - 50 mL)
|
≤-10 °C
|
5 each
(1 each)
|
|
|
|
|
RT
|
5 bottle
(90 mL)
|
|
|
|
Product Inserts
|
|
|
|
Certificate of analysis
|
|
|
|
SDS
|
|
|
|
Title
|
Journal
|
Year
|
|
Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection
|
|
|
|
The inflammatory profile of cerebrospinal fluid, plasma, and saliva from patients with severe neuropathic pain and healthy controls-a pilot study
|
|
|
|
Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses
|
|
|
|
Reliability of self-sampling for accurate assessment of respiratory virus viral and immunologic kinetics
|
|
|
|
Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial
|
|
|
|
|
View All
|
Order Details
Catalog No
Size
Price in USD
Qty
Meso Scale Japan 株式会社